Women's perspectives on female-initiated barrier methods for the prevention of HIV in the context of methamphetamine use and partner violence.

Jamila K Stockman, Jennifer L Syvertsen, Angela M Robertson, Natasha T Ludwig-Barron, Julie N Bergmann, Lawrence A Palinkas
Author Information
  1. Jamila K Stockman: Division of Global Public Health, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California. Electronic address: stockman78@hotmail.com.
  2. Jennifer L Syvertsen: Department of Anthropology, College of Arts and Sciences, Ohio State University, Columbus, Ohio.
  3. Angela M Robertson: Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; The Fenway Institute, Fenway Health, Boston, Massachusetts.
  4. Natasha T Ludwig-Barron: Division of Global Public Health, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California.
  5. Julie N Bergmann: Division of Global Public Health, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California.
  6. Lawrence A Palinkas: School of Social Work, University of Southern California, Los Angeles, California.

Abstract

BACKGROUND: Female-initiated barrier methods for the prevention of HIV may be an effective alternative for drug-using women who are unable to negotiate safe sex, often as a result of physical and/or sexual partner violence.
METHODS: Utilizing a SAVA (substance abuse, violence, and AIDS) syndemic framework, we qualitatively examined perspectives on female condoms and vaginal microbicides among 18 women with histories of methamphetamine abuse and partner violence in San Diego, California.
FINDINGS: Most women were not interested in female condoms owing to perceived discomfort, difficulty of insertion, time-intensive effort, and unappealing appearance. Alternatively, most women viewed vaginal microbicides as a useful method. Positive aspects included convenience, ability to disguise as a lubricant, and a sense of control and empowerment. Concerns included possible side effects, timing of application, and unfavorable characteristics of the gel. Acceptability of female-initiated barrier methods was context dependent (i.e., partner type, level of drug use and violence that characterized the sexual relationship).
CONCLUSIONS: Findings indicate that efforts are needed to address barriers identified for vaginal microbicides to increase its uptake in future HIV prevention trials and marketing of future Food and Drug Administration-approved products. Strategies should address gender-based inequalities (e.g., partner violence) experienced by drug-using women and promote female empowerment. Education on female-initiated barrier methods is also needed for women who use drugs, as well as health care providers and other professionals providing sexual health care and contraception to women with histories of drug use and partner violence.

References

  1. J Urban Health. 2001 Dec;78(4):571-80 [PMID: 11796804]
  2. Ann Intern Med. 2012 Feb 21;156(4):312-4 [PMID: 22250077]
  3. Sex Transm Dis. 2004 Nov;31(11):682-90 [PMID: 15502677]
  4. J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):581-9 [PMID: 18645513]
  5. AIDS. 2012 Apr 24;26(7):F13-9 [PMID: 22333749]
  6. AIDS Behav. 2003 Dec;7(4):339-51 [PMID: 14707531]
  7. J Interpers Violence. 2013 Sep;28(14):2831-48 [PMID: 23686617]
  8. Lancet. 2010 Jul 31;376(9738):312-4 [PMID: 20650519]
  9. AIDS Behav. 2012 Oct;16(7):1787-98 [PMID: 22790902]
  10. AIDS Behav. 2012 Oct;16(7):1775-86 [PMID: 22644068]
  11. J Fam Plann Reprod Health Care. 2005 Oct;31(4):285-7 [PMID: 16274550]
  12. Am J Public Health. 2000 Sep;90(9):1377-81 [PMID: 10983187]
  13. Subst Use Misuse. 2011;46(2-3):295-306 [PMID: 21303249]
  14. Curr Drug Abuse Rev. 2008 Nov;1(3):292-6 [PMID: 19630727]
  15. Subst Use Misuse. 2007;42(14):2207-22 [PMID: 18098001]
  16. Subst Abuse Rehabil. 2012 Feb 01;3(Suppl 1):45-57 [PMID: 24500422]
  17. J Womens Health (Larchmt). 2008 Oct;17(8):1345-51 [PMID: 18788991]
  18. Gend Med. 2008 Mar;5(1):24-35 [PMID: 18420163]
  19. Lancet. 2008 Apr 5;371(9619):1165-72 [PMID: 18395577]
  20. AIDS Behav. 2006 Jul;10(4 Suppl):S67-75 [PMID: 16799843]
  21. Best Pract Res Clin Obstet Gynaecol. 2012 Aug;26(4):503-13 [PMID: 22406260]
  22. Am J Addict. 2003 Oct-Dec;12(5):377-85 [PMID: 14660152]
  23. Am J Public Health. 2004 Jul;94(7):1165-73 [PMID: 15226138]
  24. Soc Sci Med. 2005 Jan;60(2):319-30 [PMID: 15522488]
  25. AIDS Educ Prev. 2008 Apr;20(2):107-20 [PMID: 18433317]
  26. Int J STD AIDS. 2006 Oct;17(10):652-9 [PMID: 17059633]
  27. J Womens Health (Larchmt). 2011 Jul;20(7):991-1006 [PMID: 21668380]
  28. Women Health. 2004;40(3):35-50 [PMID: 15829444]
  29. J Gen Intern Med. 2014 Jan;29(1):140-6 [PMID: 23979684]
  30. Int Fam Plan Perspect. 2004 Sep;30(3):139-45 [PMID: 15381469]
  31. Sex Transm Dis. 2000 Feb;27(2):119-26 [PMID: 10676980]
  32. J Womens Health Gend Based Med. 2000 Dec;9(10):1071-80 [PMID: 11153103]
  33. Am J Drug Alcohol Abuse. 2009;35(5):295-300 [PMID: 19591066]
  34. Addict Behav. 2006 Aug;31(8):1469-76 [PMID: 16309848]
  35. J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S98-101 [PMID: 21406997]
  36. J Psychoactive Drugs. 2007 Nov;Suppl 4:347-51 [PMID: 18284101]
  37. Health Educ Behav. 2011 Oct;38(5):471-81 [PMID: 21856885]
  38. Science. 2010 Sep 3;329(5996):1168-74 [PMID: 20643915]
  39. Cult Health Sex. 2006 Jul-Aug;8(4):351-69 [PMID: 16846943]
  40. Int J Womens Health. 2012;4:595-605 [PMID: 23204872]
  41. J Assoc Nurses AIDS Care. 2011 Jan-Feb;22(1):9-16 [PMID: 21211700]

Grants

  1. R25MH080665/NIMH NIH HHS
  2. L60MD003701/NIMHD NIH HHS
  3. R25 DA025571/NIDA NIH HHS
  4. R36 DA032376/NIDA NIH HHS
  5. R01 MH061146/NIMH NIH HHS
  6. K01 DA031593/NIDA NIH HHS
  7. T32DA023356/NIDA NIH HHS
  8. T32AI007384/NIAID NIH HHS
  9. R25MH080664/NIMH NIH HHS
  10. R01 HD077891/NICHD NIH HHS
  11. R25DA025571/NIDA NIH HHS
  12. T32 AI007384/NIAID NIH HHS
  13. R25 MH080664/NIMH NIH HHS
  14. R01HD077891/NICHD NIH HHS
  15. T32 DA023356/NIDA NIH HHS
  16. L60 MD003701/NIMHD NIH HHS
  17. R25 MH080665/NIMH NIH HHS
  18. R01MH061146/NIMH NIH HHS
  19. R36DA032376/NIDA NIH HHS
  20. K01DA031593/NIDA NIH HHS

MeSH Term

Adult
Anti-Infective Agents
Attitude to Health
California
Condoms, Female
Crime Victims
Female
HIV Infections
Humans
Male
Methamphetamine
Middle Aged
Patient Satisfaction
Risk Factors
Sex Offenses
Sexual Partners
Spouse Abuse
Substance-Related Disorders
United States
Vagina
Violence
Women

Chemicals

Anti-Infective Agents
Methamphetamine

Word Cloud

Created with Highcharts 10.0.0womenviolencepartnerbarriermethodsusepreventionHIVsexualfemalevaginalmicrobicidesfemale-initiateddrug-usingabuseperspectivescondomshistoriesmethamphetamineincludedempowermentcontextedrugneededaddressfuturehealthcareBACKGROUND:Female-initiatedmayeffectivealternativeunablenegotiatesafesexoftenresultphysicaland/orMETHODS:UtilizingSAVAsubstanceAIDSsyndemicframeworkqualitativelyexaminedamong18SanDiegoCaliforniaFINDINGS:interestedowingperceiveddiscomfortdifficultyinsertiontime-intensiveeffortunappealingappearanceAlternativelyviewedusefulmethodPositiveaspectsconvenienceabilitydisguiselubricantsensecontrolConcernspossiblesideeffectstimingapplicationunfavorablecharacteristicsgelAcceptabilitydependentitypelevelcharacterizedrelationshipCONCLUSIONS:FindingsindicateeffortsbarriersidentifiedincreaseuptaketrialsmarketingFoodDrugAdministration-approvedproductsStrategiesgender-basedinequalitiesgexperiencedpromoteEducationalsodrugswellprovidersprofessionalsprovidingcontraceptionWomen's

Similar Articles

Cited By